CD4 and diabetes mellitus: Although the mechanisms stimulating the change of the immune responses are diverse, and are not fully understood yet, targeting effector CD4+ T cells and CD8+ T cells, key mediators of β cell damage, has been the focus of immunotherapeutic approaches to prevent diabetes.